Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 1;69(Suppl 1):S6-S15.
doi: 10.1093/cid/ciz395.

Microbiology and Preclinical Review of Omadacycline

James A Karlowsky  1 , Judith Steenbergen  2 , George G Zhanel  1
Affiliations
Review

Microbiology and Preclinical Review of Omadacycline

James A Karlowsky et al. Clin Infect Dis. .

Abstract

Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, vancomycin-resistant Enterococcus, and Enterobacteriaceae. Omadacycline is also active against atypical and anaerobic pathogens, including Legionella pneumophila, Mycoplasma spp., Ureaplasma spp., Bacteroides spp., and Clostridioides difficile. This review outlines the microbiology and preclinical studies of omadacycline, including its mechanism of action; spectrum of activity; protein binding; activity in the presence of surfactant, serum, normal, and pH-adjusted urine, or bacterial biofilms; postantibiotic effect; pharmacodynamic properties; and in vitro and in vivo efficacy. The results of in vitro and in vivo animal studies support the observations made in phase III clinical trials and the clinical development of omadacycline.

Keywords: antimicrobial; omadacycline; pharmacodynamics; spectrum of activity; tetracyclines.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chemical structures of tetracycline, tigecycline, and omadacycline [6].
See this image and copyright information in PMC

References

    1. NUZYRA (omadacycline) prescribing information Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817l.... Accessed 3 May 2019.
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013–508.pdf. Accessed 3 May 2019.
    1. O’Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019; 380:528–38. - PubMed
    1. O’Riordan W, Cardenas C, Sirbu A, et al. A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study). Abstract O0425 at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Madrid, Spain). 2018.
    1. Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019; 380:517–27. - PubMed

Publication types

MeSH terms